Skip to Main Content

Paper Details

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.
Gastric Cancer
10
2023
Author NameAffiliation
Manish A ShahMeyer Cancer Center at Weill Cornell Medical College
  • 1 - 1

Datasets

Release 1.2